Summit Therapeutics.
biopharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 28
What's happening
One to three months ago
Gone quiet
No new reports in 90+ days-
Chinese biopharma is gaining ground, producing oncology drugs that rival established Western pharmaceuticals like those associated with Merck.Speculative1 report4 developments inside
-
Institutional investors bought and sold stock in Summit Therapeutics.Some support1 report
-
Vertex Pharmaceuticals, Eli Lilly, and Summit Therapeutics are drugmakers with ongoing clinical trials.Some support1 report
-
Revolution Medicines and Summit Therapeutics announced a collaboration on August 19, 2025, to evaluate combination therapies.Some support3 reports1 development inside
-
Summit Therapeutics and AstraZeneca announced a partnership on July 4, 2025, to collaborate on lung cancer drug development.Speculative3 reports
-
Summit Therapeutics acquired an exclusive license from Akeso for developing bispecific assets, with ivonescimab showing strong results compared to Keytruda.Some support5 reports
-
Revolution Medicines and Summit Therapeutics are collaborating to evaluate combination therapies using RAS inhibitors and ivonescimab for targeted cancer treatment.Speculative1 report
No events began in the chosen period. Widen it, or reset.
Around Summit Therapeutics this week
News at the entities that move Summit Therapeutics most-
Akeso StructuralAkeso is expanding its clinical trials into the US through a collaboration with the Icahn School of Medicine at Mount Sinai.Moves Summit Therapeutics
-
FDA StructuralFDA conducted a nationwide product recall involving toothpaste flavored with strawberry and watermelon, featuring Barbie characters.Moves Summit Therapeutics
-
Europe StructuralPetr Pavel warned at the UN that Russia's war threatens European security, coinciding with war effects disrupting food supplies in Africa.Moves Summit Therapeutics
-
Cantor Fitzgerald Mentioned togetherTD Cowen reaffirmed a buy rating while Cantor Fitzgerald downgraded monday.com Ltd. on October 6, 2026.Moves Summit Therapeutics
-
Merck OperationalThe Schwab U.S. Dividend Equity ETF holds Abbott Laboratories, Merck, and Coca-Cola as among its top holdings.Moves Summit Therapeutics
-
AstraZeneca TransactionalAstraZeneca is relocating its registered office from Karnataka to Bengaluru, citing proximity to policy and financial ecosystems.Moves Summit Therapeutics
Connections
The 10 strongest of 28, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Akeso Structural
Summit Therapeutics relies on Akeso's core IP and engineering expertise for the co-development and commercialization of ivonescimab.
-
FDA Structural
Summit Therapeutics is currently undergoing review by the FDA, which sets the standards for drug approval and market access.
-
AstraZeneca Transactional
AstraZeneca is actively negotiating and partnering with Summit Therapeutics regarding lung cancer drug development and licensing.
-
Revolution Medicines (United States) Operational
The companies are engaged in a clinical collaboration to evaluate drug combinations for cancer treatment.
-
Merck Operational
Summit Therapeutics and Merck are direct competitors in the pharmaceutical market, with A's drug ivonescimab being clinically pitted against Merck's Keytruda.
-
Europe Structural
Summit Therapeutics holds proprietary rights and markets drugs within the European territory.
-
Elon Musk Mentioned together
The evidence places both entities in the category of high-earning tech executives.
-
Cantor Fitzgerald Mentioned together
Cantor Fitzgerald analysts have provided positive ratings and commentary on Summit Therapeutics' drug data.
Show all 10 connections
-
MIaMI Shared context
Summit Therapeutics is headquartered in Miami.
-
Leerink partners Mentioned together
Evidence is insufficient to establish a relationship between Summit Therapeutics and Leerink partners.
History
Events by the month they beganSeptember 2026
1 eventJuly 2026
2 eventsJune 2026
6 events- Chinese biopharma is gaining ground, producing oncology drugs that rival established Western pharmaceuticals like those associated with Merck.
- Vertex Pharmaceuticals, Eli Lilly, and Summit Therapeutics are drugmakers with ongoing clinical trials.
- Revolution Medicines and Summit Therapeutics announced a collaboration on August 19, 2025, to evaluate combination therapies.
- Summit Therapeutics and AstraZeneca announced a partnership on July 4, 2025, to collaborate on lung cancer drug development.
- Summit Therapeutics acquired an exclusive license from Akeso for developing bispecific assets, with ivonescimab showing strong results compared to Keytruda.
- Revolution Medicines and Summit Therapeutics are collaborating to evaluate combination therapies using RAS inhibitors and ivonescimab for targeted cancer treatment.